Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin’s lymphoma, and cancer

Figure 1 Etiopathogenetic cascade of hepatitis C virus syndrome, including both hepatic and extra-hepatic disorders, is a multifactorial and multistep process: The remote events include hepatitis C virus infection, predisposing genetic factors and, possibly, unknown environmental/toxic triggers (Left). The HCV-driven immune-system alterations with prominent “benign” lymphoproliferation, from one side, and oncogenic alterations, from another side, may be the result of different pathogenetic mechanisms not mutually exclusive, through a multifactorial and multistep process: Viral antigens (core, envelope E2, NS3, NS4, NS5A proteins) may exert a chronic stimulus on the host immune system, the high-affinity binding between HCV-E2 and CD81 and consequent t(14;18) translocation with bcl-2 proto-oncogene activation, a cross-reaction between particular HCV antigens and host autoantigens, i.e., a molecular mimicry mechanism, and a direct infection of B-lymphocytes by HCV responsible for neoplastic cell transformation. Predisposing host factors may include particular HLA alleles, and both metabolic and hormonal conditions. The main consequence is a “benign” B-cell proliferation with production of various autoantibodies, among which RF and cryo- and non-cryoprecipitable IC. These serological alterations may be correlated with different organ- and non-organ-specific autoimmune disorders, including the systemic manifestations of MCs, or cryoglobulinemic vasculitis. Moreover, the activation of Bcl2 proto-oncogene, responsible for prolonged B cell survival, may be a predisposing condition to other genetic aberrations (c-myc, Bcl6, and p53 activation), which may lead to frank B cell lymphomas (B-NHL) and other malignancies (HCC: Hepatocellular carcinoma; PTC: Papillary thyroid cancer). The appearance of malignant neoplasias can be seen in a small but significant percentage of patients, usually as a late complication. Both immunological and neoplastic disorders show a clinico-serological and pathological overlap. Often, autoimmune organ-specific manifestations may evolve to systemic conditions, such as mixed cryoglobulinemia syndrome, and less frequently to overt malignancies. Conversely, it is not uncommon that patients with malignancies develop one or more autoimmune manifestations. In this scenario, MCs is at the crossing road between autoimmune and neoplastic disorders; Right: There are not comprehensive therapeutical guidelines for the HCV syndrome because of the complexity of its pathogenetic and clinico-prognostic characteristics; we can adopt in part the therapeutical strategy used for MCs, which often encompasses the different clinical variants of HCV syndrome. This therapeutical approach is essentially based on three main levels of intervention: the etiological treatment by means of antiviral drugs directed at HCV eradication, the pathogenetic therapies with immunomodulating/antineoplastic drugs, and the pathogenetic/symptomatic therapies such as corticosteroids and plasma exchange (see also text). HCV: Hepatitis C virus; IC: Immune complexes; SS: Sicca syndrome; PCT: Porphyria cutanea tarda; RF: Rheumatoid factor; MCs: Mixed cryoglobulinemia syndrome; CPX: Cyclophosphamide.

Figure 2 Patients with chronic hepatitis C virus infection may develop a complex of both hepatic and extra-hepatic disorders. Hepatitis C virus (HCV) syndrome represents an important example of coexistence of autoimmune and neoplastic conditions in humans; moreover, it can be one of the most useful models of study of the complex interactions between autoimmunity and oncogenesis[4] (Figure 2).

Figure 3 Schematic representation of the constellation of hepatitis C virus -associated disorders, varying from the great number of individuals with asymptomatic hepatitis C virus infection to patients with one or more harmful manifestations. Epidemiological studies demonstrated a great geographical heterogeneity among different HCV-associated disorders, as well as with important discrepancies with regards to their prevalence reported in clinical studies from the same country; this latter discrepancy may be dependent on specific specializations and/or variable methodological approaches (sample sizes, choice of patients and/or control subjects) of investigators from different referring centers. HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma.

Figure 4 The main serological, clinical, and pathological hallmarks of mixed cryoglobulinemia syndrome, or cryoglobulinemic vasculitis: A: On the right serum cryoprecipitate (evaluated after 7 d storage at 4 °C) composed by polyclonal IgG (autoantigen) and monoclonal IgMk (autoantibody) immune-complexes, compared to normal serum sample; B: Recent onset, palpable purpuric lesions of the lower limbs; C: Sock-like ochraceous hyperpigmentation of the legs and feet, consequence of repeated episodes of purpura; D: Severe, necrotizing vasculitic skin lesion of the leg; E: Typical histological pattern of cutaneous leukocytoclastic vasculitis involving the small vessels and characterized by diffuse fibrinoid necrosis and disintegrated neutrophil permeation of the vessel walls; F: Wide non-healing skin ulcer, often resistant to treatment.

Figure 5 Immune-mediated thyroid involvement and diabetes type 2 can be observed in a significant percentage of patients with hepatitis C virus infection. The figure summarizes the possible etiopathogenetic mechanisms involved in these two endocrine disorders. HCV thyroid infection may act by upregulating CXCL10 gene expression and secretion in thyrocytes (and pancreatic b-cells); CXCL10 may promote the recruitment of Th1 lymphocytes, which secrete interferon-γ (IFN-γ) and tumor necrosis factor-α (TNFα). In turn, these cytokines may induce CXCL10 secretion by thyrocytes (and pancreatic b-cells), thus perpetuating the immune cascade. The consequence may be the appearance of thyroid autoimmune disorders and/or diabetes type 2 in genetically predisposed subjects. HCV: Hepatitis C virus.